Figure 1.
Expression profile and prognostic value of SLAMF8 in glioma. Expression of SLAMF8 differed by grade, histopathologic classification, and molecular and TCGA subtype (A). SLAMF8 was specifically enriched in mesenchymal subtype (B) in CGGA. SLAMF8 influenced glioma prognosis in CGGA (C‐F) and TCGA (G‐J) cohorts. SLAMF8 predicted 1‐year, 3‐year, and 5‐year of survival in CGGA (K‐M)